Literature DB >> 15070101

Lactose surface modification by decantation: are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixtures?

Nazrul Islam1, Peter Stewart, Ian Larson, Patrick Hartley.   

Abstract

PURPOSE: The role of fine lactose in the dispersion of salmeterol xinafoate (SX) from lactose mixtures was studied by modifying the fine lactose concentration on the surface of the lactose carriers using wet decantation.
METHODS: Fine lactose was removed from lactose carriers by wet decantation using ethanol saturated with lactose. Particle sizing was achieved by laser diffraction. Fine particle fractions (FPFs) were determined by Twin Stage Impinger using a 2.5% SX mixture, and SX was analyzed by a validated high-performance liquid chromatography method. Adhesion forces between probes of SX and silica and the lactose surfaces were determined by atomic force microscopy.
RESULTS: FPFs of SX were related to fine lactose concentration in the mixture for inhalation grade lactose samples. Reductions in FPF (2-tp 4-fold) of Aeroflo 95 and 65 were observed after removing fine lactose by wet decantation; FPFs reverted to original values after addition of micronized lactose to decanted mixtures. FPFs of SX of sieved and decanted fractions of Aeroflo carriers were significantly different (p < 0.001). The relationship between FPF and fine lactose concentration was linear. Decanted lactose demonstrated surface modification through increased SX-lactose adhesion forces; however, any surface modification other than removal of fine lactose only slightly influenced FPF.
CONCLUSIONS: Fine lactose played a key and dominating role in controlling FPF. SX to fine lactose ratios influenced dispersion of SX with maximum dispersion occurring as the ratio approached unity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15070101     DOI: 10.1023/B:PHAM.0000019304.91412.18

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

1.  [Effect of mixing of fine carrier particles on dry powder inhalation property of salbutamol sulfate (SS)].

Authors:  K Iida; H Leuenberger; L M Fueg; R Müller-Walz; H Okamoto; K Danjo
Journal:  Yakugaku Zasshi       Date:  2000-01       Impact factor: 0.302

2.  Influence of physico-chemical carrier properties on the in vitro aerosol deposition from interactive mixtures.

Authors:  Margaret D Louey; Sultana Razia; Peter J Stewart
Journal:  Int J Pharm       Date:  2003-02-18       Impact factor: 5.875

3.  The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate.

Authors:  H Larhrib; X M Zeng; G P Martin; C Marriott; J Pritchard
Journal:  Int J Pharm       Date:  1999-11-25       Impact factor: 5.875

4.  Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers.

Authors:  P Lucas; K Anderson; J N Staniforth
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

5.  Particle interactions involved in aerosol dispersion of ternary interactive mixtures.

Authors:  Margaret D Louey; Peter J Stewart
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

6.  Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation.

Authors:  X M Zeng; G P Martin; S K Tee; A A Ghoush; C Marriott
Journal:  Int J Pharm       Date:  1999-05-25       Impact factor: 5.875

7.  The influence of carrier morphology on drug delivery by dry powder inhalers.

Authors:  X M Zeng; G P Martin; C Marriott; J Pritchard
Journal:  Int J Pharm       Date:  2000-04-25       Impact factor: 5.875

8.  The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate.

Authors:  S K Tee; C Marriott; X M Zeng; G P Martin
Journal:  Int J Pharm       Date:  2000-11-04       Impact factor: 5.875

9.  A new powder design method to improve inhalation efficiency of pranlukast hydrate dry powder aerosols by surface modification with hydroxypropylmethylcellulose phthalate nanospheres.

Authors:  Y Kawashima; T Serigano; T Hino; H Yamamoto; H Takeuchi
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

10.  Characterization of a surface modified dry powder inhalation carrier prepared by "particle smoothing".

Authors:  P M Young; D Cocconi; P Colombo; R Bettini; R Price; D F Steele; M J Tobyn
Journal:  J Pharm Pharmacol       Date:  2002-10       Impact factor: 3.765

View more
  19 in total

1.  Agglomerate strength and dispersion of salmeterol xinafoate from powder mixtures for inhalation.

Authors:  Handoko Adi; Ian Larson; Herbert Chiou; Paul Young; Daniela Traini; Peter Stewart
Journal:  Pharm Res       Date:  2006-09-14       Impact factor: 4.200

Review 2.  The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations.

Authors:  Matthew D Jones; Robert Price
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

3.  An investigation into the dispersion mechanisms of ternary dry powder inhaler formulations by the quantification of interparticulate forces.

Authors:  Matthew D Jones; Jennifer C Hooton; Michelle L Dawson; Alan R Ferrie; Robert Price
Journal:  Pharm Res       Date:  2007-10-19       Impact factor: 4.200

4.  The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations.

Authors:  Jagdeep Shur; Haggis Harris; Matthew D Jones; J Sebastian Kaerger; Robert Price
Journal:  Pharm Res       Date:  2008-02-01       Impact factor: 4.200

5.  Multi-scale modelling of powder dispersion in a carrier-based inhalation system.

Authors:  Zhenbo Tong; Hidehiro Kamiya; Aibing Yu; Hak-Kim Chan; Runyu Yang
Journal:  Pharm Res       Date:  2014-12-17       Impact factor: 4.200

6.  Engineered mannitol ternary additives improve dispersion of lactose-salbutamol sulphate dry powder inhalations.

Authors:  Waseem Kaialy; Ali Nokhodchi
Journal:  AAPS J       Date:  2013-04-17       Impact factor: 4.009

Review 7.  Addressing the Regulatory and Scientific Challenges with Generic Orally Inhaled Drug Products.

Authors:  Bryan Newman; Kimberly Witzmann
Journal:  Pharmaceut Med       Date:  2020-04

8.  Evaluation of granulated lactose as a carrier for DPI formulations 1: effect of granule size.

Authors:  Ping Du; Ju Du; Hugh D C Smyth
Journal:  AAPS PharmSciTech       Date:  2014-06-25       Impact factor: 3.246

9.  Investigation of electrostatic behavior of a lactose carrier for dry powder inhalers.

Authors:  Keat Theng Chow; Kewu Zhu; Reginald B H Tan; Paul W S Heng
Journal:  Pharm Res       Date:  2008-06-26       Impact factor: 4.200

10.  Improving Dry Powder Inhaler Performance by Surface Roughening of Lactose Carrier Particles.

Authors:  Bernice Mei Jin Tan; Lai Wah Chan; Paul Wan Sia Heng
Journal:  Pharm Res       Date:  2016-04-18       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.